Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke

Thrombolytic treatment (tissue-type plasminogen activator [tPA]) is only recommended for acute ischemic stroke patients with stroke onset time

Saved in:
Bibliographic Details
Published in:PloS one 2016-02, Vol.11 (2), p.e0148106-e0148106
Main Authors: Pandya, Ankur, Eggman, Ashley A, Kamel, Hooman, Gupta, Ajay, Schackman, Bruce R, Sanelli, Pina C
Format: Article
Language:English
Subjects:
Accounting
Biology and Life Sciences
Care and treatment
Computer simulation
Cost benefit analysis
Cost effectiveness
Costs
Driving while intoxicated
Economic aspects
Health aspects
Health care policy
Ischemia
Magnetic resonance imaging
Mathematical analysis
Medical imaging
Medicine and Health Sciences
Models, Economic
Models, Neurological
Neuroimaging
Neuroimaging - economics
Neuroimaging - methods
Neurology
NMR
Nuclear magnetic resonance
Patients
Physical Sciences
Probability distribution
Research and Analysis Methods
Sensitivity
Sensitivity analysis
Simulation
Sleep
Social Sciences
Strategy
Stroke
Stroke - diagnosis
Stroke - economics
Stroke - therapy
t-Plasminogen activator
Thrombolysis
Tissue plasminogen activator
Travel
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Thrombolytic treatment (tissue-type plasminogen activator [tPA]) is only recommended for acute ischemic stroke patients with stroke onset time
ISSN:1932-6203
1932-6203
DOI:10.1371/journal.pone.0148106